The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Open accessAbstract
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.Methods We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759.Findings Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease.Interpretation Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Experimental — accuracy not yet measuredIn the citing paper
“Nivolumab (BMS-936558, ONO-4538, or MDX1106, trade name Opdivo; Bristol-Myers Squibb, Princeton, NJ, USA) is a first-in-class fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) inhibitor that suppresses PD-1 activity through selectively targeting and blocking the interaction between ligands (PD-L1 and PD-L2) and PD-1 receptor [35].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [35]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citation
Cited by
Sorted by citations
Items 101–200 of 1,000
Macrophages, Inflammation, and Lung Cancer
Conway, E. M., Pikor, L. A., Kung, S. H. Y., Hamilton, M. J., Lam, S. C., Lam, W. L., & Bennewith, K. L. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1545ci · Cited by 295
Scientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.012 · Cited by 284
Self-citationNivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Guo, L., Zhang, H., & Chen, B. (2017) · Journal of Cancer · doi:10.7150/jca.17144 · Cited by 291
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Atsaves, V., Leventaki, V., Rassidakis, G. Z., & Claret, F. X. (2019) · Cancers · doi:10.3390/cancers11071037 · Cited by 295
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 281
He, Y., Yu, H., Rozeboom, L. M., Rivard, C. J., Ellison, K. E., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.019 · Cited by 277
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Bajaj, G., Wang, X., Agrawal, S., Gupta, M., Roy, A., & Feng, Y. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12143 · Cited by 268
Patterns of Response and Progression to Immunotherapy
Borcoman, É., Nandikolla, A. G., Long, G. V., Goel, S., & Tourneau, C. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 267
Markers of T Cell Senescence in Humans
Xu, W., & Larbi, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081742 · Cited by 261
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
Sacher, A. G., & Gandhi, L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0639 · Cited by 255
Tirumani, S. H., Ramaiya, N. H., Keraliya, A. R., Bailey, N., Ott, P. A., Hodi, F. S., & Nishino, M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0102 · Cited by 257
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A. A., Gandhi, L., Garon, E. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0382-2 · Cited by 253
Self-citationWeber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248
Biological effects of radiation on cancer cells
Wang, J., Wang, H., & Qian, H. (2018) · Military Medical Research · doi:10.1186/s40779-018-0167-4 · Cited by 247
Shi, V. J., Rodić, N., Gettinger, S. N., Leventhal, J. S., Neckman, J. P., Girardi, M., Bosenberg, M., & Choi, J. N. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.2226 · Cited by 243
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Wang, Y., Abu‐Sbeih, H., Mao, E., Ali, N., Qiao, W., Trinh, V. A., Zobniw, C. M., Johnson, D. H., Samdani, R. T., Lum, P. J., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy104 · Cited by 245
Wang, X., Yang, X., Zhang, C., Wang, Y., Cheng, T., Duan, L., Tong, Z., Tan, S., Zhang, H., Saw, P. E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921445117 · Cited by 245
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Moreira, A., Loquai, C., Pföhler, C., Kähler, K. C., Knauß, S., Heppt, M. V., Gutzmer, R., Dimitriou, F., Meier, F. E., Mitzel-Rink, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.033 · Cited by 242
Learning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight · doi:10.1172/jci.insight.122092 · Cited by 233
“Introduction Cancer immunotherapy has succeeded in providing unprecedented clinical benefit to a subset of patients with many cancer types, including melanoma (1) and non–small cell lung cancer (2), while failing in others.”
BackgroundNeoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J. D., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 233
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
Kuriakose, A., Chirmule, N. B., & Nair, P. (2016) · Journal of Immunology Research · doi:10.1155/2016/1298473 · Cited by 231
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Håkansson, L., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 235
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
Pietanza, M. C., Byers, L. A., Minna, J. D., & Rudin, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2958 · Cited by 229
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
La-Beck, N. M., Jean, G. W., Huynh, C., Alzghari, S. K., & Lowe, D. B. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1643 · Cited by 220
Dine, J. L., Gordon, R., Shames, Y., Kasler, M. K., & Barton‐Burke, M. (2017) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_4_17 · Cited by 221
Wang, D. Y., Ye, F., Zhao, S., & Johnson, D. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344805 · Cited by 220
Grabovska, Y., Mackay, A. G., O’Hare, P., Crosier, S., Finetti, M. A., Schwalbe, E. C., Pickles, J. C., Fairchild, A. R., Avery, A., Cockle, J. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18070-y · Cited by 211
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Grigg, C. M., & Rizvi, N. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0153-x · Cited by 219
Self-citationEfficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 213
Osta, B. E. E., Hu, F., Sadek, R. A., Chintalapally, R., & Tang, S. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 208
Cho, J. Y., Kim, J., Lee, J. S., Kim, Y. J., Kim, S. H., Lee, Y. J., Cho, Y., Yoon, H. I., Lee, J. H., Lee, C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.015 · Cited by 209
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
Goldinger, S. M., Stieger, P., Meier-Schiesser, B., Micaletto, S., Contassot, E., French, L. E., & Dummer, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2872 · Cited by 205
Treatment after progression in the era of immunotherapy
Billan, S., Kaidar‐Person, O., & Gil, Z. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30328-4 · Cited by 205
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 207
Brunnström, H., Johansson, A., Westbom-Fremer, S., Backman, M., Djureinovic, D., Patthey, A., Isaksson‐Mettävainio, M., Gulyás, M., & Micke, P. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.59 · Cited by 204
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Schalper, K. A., Carvajal‐Hausdorf, D., McLaughlin, J. F., Altan, M., Velcheti, V., Gaule, P., Sanmamed, M. F., Chen, L., Herbst, R. S., & Rimm, D. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0150 · Cited by 202
A Dual Immunotherapy Nanoparticle Improves T‐Cell Activation and Cancer Immunotherapy
Mi, Y., Smith, C. C., Yang, F., Qi, Y., Roche, K. C., Serody, J. S., Vincent, B. G., & Wang, A. Z. (2018) · Advanced Materials · doi:10.1002/adma.201706098 · Cited by 200
Manohar, S., Kompotiatis, P., Thongprayoon, C., Cheungpasitporn, W., Herrmann, J., & Herrmann, S. M. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy105 · Cited by 198
Aguiar, P. N., de Mello, R. A., Hall, P. S., Tadokoro, H., & Lopes, G. D. L., Jr. (2017) · Immunotherapy · doi:10.2217/imt-2016-0150 · Cited by 199
Minguet, J., Smith, K. H., & Bramlage, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29915 · Cited by 198
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Wang, Y., Lee, H., Hsu, J. L., Yu, D., & Hung, M. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00670-x · Cited by 198
Park, Y., Kuen, D., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 198
van den Berg, J. H., Heemskerk, B., van Rooij, N., Gomez-Eerland, R., Michels, S., van Zon, M., de Boer, R., Bakker, N. A. M., Jorritsma‐Smit, A., van Buuren, M. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000848 · Cited by 194
Mu, W., Tunali, I., Gray, J. E., Qi, J., Schabath, M. B., & Gillies, R. J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04625-9 · Cited by 194
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Vigarios, É., Epstein, J. B., & Sibaud, V. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3629-4 · Cited by 195
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000256 · Cited by 189
Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy
Carbone, D. P., Gandara, D. R., Antonia, S. J., Zielinski, C. C., & Paz-Ares, L. G. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000551 · Cited by 198
Self-citationLung Cancer in the Era of Precision Medicine
Politi, K. A., & Herbst, R. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2748 · Cited by 190
Tokito, T., Azuma, K., Kawahara, A., Ishii, H., Yamada, K., Matsuo, N., Kinoshita, T., Mizukami, N., Ono, H., Kage, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.020 · Cited by 193
Current state of immunotherapy for non-small cell lung cancer
Malhotra, J. D., Jabbour, S. K., & Aisner, J. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.01 · Cited by 193
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186
Li, H. Y., McSharry, M. V., Bullock, B., Nguyen, T. T., Kwak, J., Poczobutt, J. M., Sippel, T. R., Heasley, L. E., Weiser-Evans, M. C. M., Clambey, E. T., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0365 · Cited by 193
Zhang, J., Chen, B., Gan, C., Sun, H., Zhang, J., & Feng, L. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s436038 · Cited by 190
Rebelatto, M. C., Midha, A., Mistry, A., Sabalos, C. M., Schechter, N., Li, X., Jin, X., Steele, K. E., Robbins, P. B., Blake-Haskins, J. A., et al. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0545-8 · Cited by 184
Bastman, J. J., Serracino, H. S., Zhu, Y., Koenig, M. R., Mateescu, V., Sams, S. B., Davies, K. D., Raeburn, C. D., McIntyre, R. C., Haugen, B. R., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4227 · Cited by 182
Wang, Z., Wu, L., Li, B., Cheng, Y., Li, X., Wang, X., Han, L., Wu, X., Fan, Y., Yu, Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00727 · Cited by 186
Chuzi, S. E., Tavora, F. R. F., Cruz, M. R. D. S., Costa, R. L. B., Chae, Y. K., Carneiro, B. A., & Giles, F. J. (2017) · Cancer Management and Research · doi:10.2147/cmar.s136818 · Cited by 181
Barbee, M. S., Ogunniyi, A., Horvat, T. Z., & Dang, T.-O. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015586218 · Cited by 184
Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., GENET, M. D., Gritsina, G., Győrffy, B., Brastianos, P. K., Binder, D. C., Sosman, J. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0120 · Cited by 182
PD-L1/PD-1 Axis in Glioblastoma Multiforme
Litak, J., Mazurek, M., Grochowski, C., Kamieniak, P., & Roliński, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215347 · Cited by 187
CRISPR–Cas: a tool for cancer research and therapeutics
Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 185
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Kawakami, H., Tanizaki, J., Tanaka, K., Haratani, K., Hayashi, H., Takeda, M., Kamata, K., Takenaka, M., Kimura, M., Chikugo, T., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0453-0 · Cited by 178
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Asano, T., Meguri, Y., Yoshioka, T., Kishi, Y., Iwamoto, M., Nakamura, M., Sando, Y., Yagita∥, H., Koreth, J., Kim, H. T., et al. (2017) · Blood · doi:10.1182/blood-2016-09-741629 · Cited by 183
Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 181
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 179
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas
Menter, T., Bodmer-Haecki, A., Dirnhofer, S., & Tzankov, A. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.03.005 · Cited by 165
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
Iron induces anti-tumor activity in tumor-associated macrophages
Costa da Silva, M., Breckwoldt, M. O., Vinchi, F., Correia, M. P., Stojanovic, A., Thielmann, C. M., Meister, M., Muley, T., Warth, A., Platten, M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01479 · Cited by 164
Rehman, J., Han, G., Carvajal‐Hausdorf, D., Wasserman, B. E., Pelekanou, V., Mani, N. L., McLaughlin, J. F., Schalper, K. A., & Rimm, D. L. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.186 · Cited by 167
Ferrara, R., Mezquita, L., Auclin, E., Chaput, N., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.003 · Cited by 163
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Passiglia, F., Bronte, G., Bazan, V., Natoli, C., Rizzo, S., Galvano, A., Listì, A., Cicero, G., Rolfo, C. D., Santini, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7582 · Cited by 166
Abdel-Rahman, O. M., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O. M., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 163
Park, H. J., Kim, K. W., Pyo, J., Suh, C. H., Yoon, S., Hatabu, H., & Nishino, M. (2020) · Radiology · doi:10.1148/radiol.2020200443 · Cited by 162
Xing, Y., Chand, G., Liu, C., Cook, G., O’Doherty, J., Zhao, L., Wong, N. C. L., Meszaros, L. K., Ting, H. H., & Zhao, J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224170 · Cited by 164
Chen, D., Sheng, H., Zhang, D., Jin, Y., Zhao, B.-T., Chen, N., Song, K., & Xu, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01475-8 · Cited by 162
Vaccine-based immunotherapeutic approaches to gliomas and beyond
Weller, M., Roth, P., Preusser, M., Wick, W., Reardon, D. A., Platten, M., & Sampson, J. H. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.64 · Cited by 162
Felip, E., Ardizzoni, A., Ciuleanu, T., Cobo, M., Лактионов, К. К., Szilasi, M., Califano, R., Carcereny, E., Griffiths, R., Paz-Ares, L. G., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.019 · Cited by 163
Self-citationAguiar, P. N., Santoro, I. L., Tadokoro, H., Lopes, G. D. L., Jr., Filardi, B. A., Oliveira, P. F., Mountzios, G., & de Mello, R. A. (2016) · Immunotherapy · doi:10.2217/imt-2015-0002 · Cited by 163
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 168
Bang, A., Wilhite, T. J., Pike, L., Cagney, D. N., Aizer, A. A., Taylor, A., Spektor, A., Krishnan, M. S., Ott, P. A., Balboni, T. A., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.02.003 · Cited by 159
Parra, E. R., Villalobos, P. A., Mino, B., & Rodriguez‐Canales, J. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000531 · Cited by 157
Khunger, M., Hernández, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J. P., Mukhopadhyay, S., Schalper, K. A., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 158
Xu, J., Wang, H., Xu, L., Chao, Y., Wang, C., Han, X., Dong, Z., Chang, H., Peng, R., Cheng, Y., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.037 · Cited by 155
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer
Tang, C., Hobbs, B., Amer, A., Li, X., Behrens, C., Canales, J. R., Cuentas, E. P., Villalobos, P., Fried, D., Chang, J. Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20471-5 · Cited by 154
Planchard, D., Reinmuth, N., Орлов, С. В., Fischer, J. R., Sugawara, S., Mańdziuk, S., Márquez-Medina, D., Novello, S., Takeda, Y., Soo, R. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.006 · Cited by 153
Self-citationHayes, D. N., Waes, C. V., & Seiwert, T. Y. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1086 · Cited by 153
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Sun, X., Roudi, R., Dai, T., Chen, S., Fan, B., Li, H., Zhou, Y., Zhou, M., Zhu, B., Yin, C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5701-6 · Cited by 150
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
Mender, I., Zhang, A., Ren, Z., Han, C., Deng, Y., Siteni, S., Li, H., Zhu, J., Vemula, A., Shay, J. W., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.020 · Cited by 149
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 149
Desai, J., Deva, S., Lee, J. S., Lin, C., Yen, C.-J., Chao, Y., Keam, B., Jameson, M. B., Hou, M., Kang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000453 · Cited by 149
Photodynamic Therapy of Non–Small Cell Lung Cancer. Narrative Review and Future Directions
Shafirstein, G., Battoo, A., Harris, K. N., Baumann, H., Gollnick, S. O., Lindenmann, J., & Nwogu, C. E. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201509-650fr · Cited by 147
Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer
Nishino, M., Chambers, E. S., Chong, C. R., Ramaiya, N. H., Gray, S. W., Marcoux, J. P., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0267 · Cited by 147
Immune Checkpoint in Glioblastoma: Promising and Challenging
Huang, J., Liu, F., Liu, Z., Tang, H., Wu, H., Gong, Q.-N., & Chen, J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00242 · Cited by 153
Briere, D. M., Sudhakar, N., Woods, D. M., Hallin, J. F., Engstrom, L. D., Aranda, R., Chiang, H., Sodré, A. L., Olson, P., Weber, J. S., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2091-y · Cited by 149
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Wang, Q., & Wu, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.015 · Cited by 146
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Cui, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.562315 · Cited by 156
Metadata
- Authors
- Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Souquet, P.-J., Baldini, E., Cappuzzo, F., Chouaid, C., Dowlati, A., Sanborn, R., Lopez-Chavez, A., Grohe, C., Huber, R. M., Harbison, C. T., Baudelet, C., Lestini, B. J., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Institut Gustave Roussy (FR)
- University of North Carolina at Chapel Hill (US)
- Roswell Park Comprehensive Cancer Center (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Azienda Ospedaliera S.Maria (IT)
- Hôpital Civil, Strasbourg (FR)
- The Ohio State University Wexner Medical Center (US)
- UC Davis Comprehensive Cancer Center (US)
- Mount Sinai Beth Israel (US)
- Lehigh Valley Hospital (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- University Hospital Cologne (DE)
- Hospices Civils de Lyon (FR)
- Ospedale di Livorno (IT)
- University Hospitals of Cleveland (US)
- Providence Portland Medical Center (US)
- German Center for Lung Research (DE)
- Princeton University (US)
- Emory University (US)
- Corresponding author
- Rizvi, Naiyer A
- ORCID
- Rizvi, Naiyer A
- Mazières, Julien
- Planchard, David
- Stinchcombe, Thomas E
- Dy, Grace K
- Antonia, Scott J
- Horn, Leora
- Mennecier, Bertrand
- Otterson, Gregory A
- Campos, Luis T
- Gandara, David R
- Levy, Benjamin P
- Nair, Suresh G
- Zalcman, Gérard
- Wolf, Jürgen
- Cappuzzo, Federico
- Chouaid, Christos
- Dowlati, Afshin
- Sanborn, Rachel
- Huber, Rudolf M
- Ramalingam, Suresh S
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 16
- Issue
- 3
- Pages
- 257-265
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5726228
- OpenAlex
- W2106511606
- Cited by
- 1,415
- References
- 36
- Citations by year
- 2026: 23 · 2025: 35 · 2024: 62 · 2023: 84 · 2022: 81 · 2021: 114 · 2020: 128 · 2019: 135 · 2018: 179 · 2017: 228 · 2016: 229 · 2015: 111
- FWCI
- 108.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- PD-1 inhibitors, lung squamous cell carcinoma, refractory lung cancer, objective response rate, treatment safety, pneumonitis, immune-related adverse events, immune checkpoint blockade, non-relapse mortality, ischemic stroke, pneumonia, fatigue, diarrhea, previously treated patients, duration of response, stable disease, time to response
- MeSH terms
- Nivolumab, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Administration Schedule, Europe, Female, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Risk Factors, Time Factors, United States, Signal Transduction, Comorbidity, Treatment Outcome, Disease Progression, Disease-Free Survival, Kaplan-Meier Estimate, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
